Omeros Corp OMER
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OMER is a good fit for your portfolio.
News
-
Omeros Corporation Reports Third Quarter 2023 Financial Results
-
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
-
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
-
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
-
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
-
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
Trading Information
- Previous Close Price
- $2.54
- Day Range
- $2.29–2.50
- 52-Week Range
- $0.93–7.77
- Bid/Ask
- $2.44 / $2.45
- Market Cap
- $154.65 Mil
- Volume/Avg
- 121,279 / 737,240
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 196
- Website
- https://www.omeros.com
Valuation
|
Metric
|
OMER
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
OMER
Financial Strength
|
Metric
|
OMER
|
|---|---|
Quick Ratio | 2.35 |
Current Ratio | 2.39 |
Interest Coverage | −5.20 |
Quick Ratio
OMER
Profitability
|
Metric
|
OMER
|
|---|---|
Return on Assets (Normalized) | −32.23% |
Return on Equity (Normalized) | −840.03% |
Return on Invested Capital (Normalized) | −42.19% |
Return on Assets
OMER
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lzsr | $454.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gqlphj | $90.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jpqkhjc | $89.7 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Jkcmtqp | $40.2 Bil | |
MRNA
| Moderna Inc | Wlx | $30.5 Bil | |
ARGX
| argenx SE ADR | Rxrg | $27.3 Bil | |
BNTX
| BioNTech SE ADR | Nsl | $23.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bwsgwqk | $21.7 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wnpfrl | $17.8 Bil | |
INCY
| Incyte Corp | Crbvmk | $12.3 Bil |